Clinical Trial Update: N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial investigating N-Acetylcysteine augmentation in treatment-refractory obsessive-compulsive disorder has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Yale University | Conditions: Obsessive-Compulsive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2013-03-08